24 May 2019 - - US-based biotechnology company Seattle Genetics, Inc. (NASDAQ: SGEN) has appointed Robin G. Taylor, M.B.A., Ph.D., as chief commercial officer, the company said.

Taylor brings 18 years of biotechnology and pharmaceutical company experience in the commercialisation of oncology drugs, including significant marketing, launch and global product strategy roles at both Genentech/Roche and AstraZeneca.

He contributed to several leading global brands, including Tecentriq (atezolizumab), Alecensa (alectinib), Avastin (bevacizumab) and Herceptin (trastuzumab).

Robin Taylor has extensive global development and commercialization oncology experience.

Most recently, he served as vice president, Immuno-Oncology Franchise Head, Oncology Business Unit at AstraZeneca, where he led global marketing and product teams for Imfinzi (durvalumab), an immunotherapy approved for metastatic urothelial carcinoma, and Stage III unresectable non-small cell lung cancer.

Prior to joining AstraZeneca, Taylor served in roles of increasing responsibility at Genentech, a Member of the Roche Group, from 2001 to 2018.

Most recently, he served as vice president, Cancer Immunotherapy Franchise Head, Global Product Strategy, responsible for the global development and launch of Tecentriq across multiple indications.

He received a Doctor of Philosophy, Molecular and Medical Genetics from University of Toronto, a Masters of Business Administration from University of California Berkeley, and a Bachelor of Science degree from University of British Columbia.

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives.

Adcetris (brentuximab vedotin) utilizes the company's industry-leading ADC technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Beyond Adcetris, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors.

Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary ADC technology.

Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer.

In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

The company is headquartered in Bothell, Washington, and has a European office in Switzerland.